MX2021002556A - Tratamiento del dolor postquirurgico. - Google Patents

Tratamiento del dolor postquirurgico.

Info

Publication number
MX2021002556A
MX2021002556A MX2021002556A MX2021002556A MX2021002556A MX 2021002556 A MX2021002556 A MX 2021002556A MX 2021002556 A MX2021002556 A MX 2021002556A MX 2021002556 A MX2021002556 A MX 2021002556A MX 2021002556 A MX2021002556 A MX 2021002556A
Authority
MX
Mexico
Prior art keywords
post
surgical pain
pain treatment
patient
surgical
Prior art date
Application number
MX2021002556A
Other languages
English (en)
Spanish (es)
Inventor
Barry D Quart
Thomas B Ottoboni
Original Assignee
Heron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heron Therapeutics Inc filed Critical Heron Therapeutics Inc
Publication of MX2021002556A publication Critical patent/MX2021002556A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2021002556A 2018-09-07 2019-09-06 Tratamiento del dolor postquirurgico. MX2021002556A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728732P 2018-09-07 2018-09-07
US201962860190P 2019-06-11 2019-06-11
PCT/US2019/050079 WO2020051543A1 (en) 2018-09-07 2019-09-06 Post-surgical pain treatment

Publications (1)

Publication Number Publication Date
MX2021002556A true MX2021002556A (es) 2021-06-15

Family

ID=68138775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002556A MX2021002556A (es) 2018-09-07 2019-09-06 Tratamiento del dolor postquirurgico.

Country Status (12)

Country Link
US (1) US20200078363A1 (enExample)
EP (1) EP3846811B1 (enExample)
JP (2) JP2021536477A (enExample)
KR (1) KR20210060492A (enExample)
CN (1) CN112955144A (enExample)
AU (1) AU2019337104B2 (enExample)
BR (1) BR112021004331A2 (enExample)
CA (1) CA3111570A1 (enExample)
MA (1) MA53553A (enExample)
MX (1) MX2021002556A (enExample)
TW (1) TW202023567A (enExample)
WO (1) WO2020051543A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992485B2 (en) * 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) * 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
JP2021512091A (ja) * 2018-01-30 2021-05-13 ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. Nk−1受容体アンタゴニストのエマルジョン製剤の投与方法
CN115515581A (zh) * 2020-01-10 2022-12-23 帕西拉制药股份有限公司 通过给予缓释脂质体麻醉组合物治疗疼痛
CA3205758A1 (en) * 2021-01-29 2022-08-04 William Taylor Compositions and methods for sustained treatment of pain
WO2023154293A1 (en) * 2022-02-08 2023-08-17 Saint Cyr Michael Hector Anesthetic formulations and methods
CN116898977B (zh) * 2022-07-20 2025-07-15 四川大学华西医院 一种麻醉镇痛的联合用药物
CN116041342B (zh) * 2022-12-30 2024-02-20 加立(深圳)生物科技有限公司 罗哌卡因/美洛昔康盐的一水合物i晶型、药物组合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508961A (ja) * 2002-11-12 2006-03-16 オメロス コーポレイション 腫瘍細胞接着、疼痛、および炎症を阻害するための灌注溶液および方法
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
US20100316678A1 (en) * 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
US8992951B2 (en) * 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US9744163B2 (en) * 2013-03-15 2017-08-29 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
CA3174824A1 (en) * 2014-04-21 2015-10-29 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US9801945B2 (en) * 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US11083730B2 (en) * 2014-04-21 2021-08-10 Heron Therapeutics, Inc. Long-acting polymeric delivery systems

Also Published As

Publication number Publication date
CA3111570A1 (en) 2020-03-12
EP3846811A1 (en) 2021-07-14
JP2021536477A (ja) 2021-12-27
AU2019337104A1 (en) 2021-03-25
BR112021004331A2 (pt) 2021-08-03
US20200078363A1 (en) 2020-03-12
TW202023567A (zh) 2020-07-01
AU2019337104B2 (en) 2025-05-15
EP3846811C0 (en) 2025-11-05
WO2020051543A1 (en) 2020-03-12
MA53553A (fr) 2021-07-14
CN112955144A (zh) 2021-06-11
EP3846811B1 (en) 2025-11-05
JP2025010592A (ja) 2025-01-22
KR20210060492A (ko) 2021-05-26

Similar Documents

Publication Publication Date Title
SA521421973B1 (ar) عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
MX2017005875A (es) Metodos para tratar enfermedades oculares.
PH12019500025A1 (en) Cancer treatment combinations
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
JOP20190191A1 (ar) وحدات شجرية علاجية
EP3817747A4 (en) TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES
EA202091640A1 (ru) Способы лечения опосредованного il-6 воспаления без иммунодепрессии
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX394957B (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
MX2025004901A (es) Tratamiento de verrugas
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2022007738A (es) Procesos e intermedios sinteticos.
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
TW201642854A (en) Fixed dose combination for pain relief without edema
MX387961B (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA202190294A1 (ru) Комбинированная терапия для лечения рака
MX2014005152A (es) Composicion farmaceutica para el tratamiento de alopatias relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol.